PedAM
Pediatric Disease Annotations & Medicines
| Disease | adenocarcinoma |
| Phenotype | C0004763|barrett\'s esophagus |
| Sentences | 46 |
| PubMedID- 24212953 | Epidemiologic studies showed that long-term use of ppi was associated with lower rates of dysplasia and adenocarcinoma in patients with barrett's esophagus [24,25]. |
| PubMedID- 21820152 | The findings of this study improve our understanding of the role that chromosomal instability and alterations of tumor suppressor genes such as cdkn2a and oncogenes such as erbb2 play in the progression of intestinal metaplasia to adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 23453294 | Patients: we studied 23 consecutive patients who underwent complete cesd for superficial esophageal carcinoma (22 squamous cell carcinomas and 1 adenocarcinoma associated with barrett's esophagus). |
| PubMedID- 22272378 | [18] found a correlation between cox2 expression and tp53 wild-type status in esophageal adenocarcinoma with barrett's esophagus as a precursor lesion, but not in scc, providing evidence that the participation of p53 in the regulation of cox2 expression in cancer may be dependent on tumor histology. |
| PubMedID- 19660251 | Rapid progression of barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. |
| PubMedID- 21375764 | In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) [2,3]. |
| PubMedID- 20188100 | However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (eac) in patients with existing barrett's esophagus (be) is unclear. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 21946284 | Whether nonerosive reflux disease (nerd) is a risk factor for barrett's esophagus (be), the precursor of esophageal adenocarcinoma, is unknown. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
| PubMedID- 21991505 | Similarly, barrett's esophagus, a precursor of esophagus adenocarcinoma, is thought to have a low prevalence among asians. |
| PubMedID- 24968432 | Pathological diagnosis was adenocarcinoma with barrett's esophagus. |
| PubMedID- 23617676 | adenocarcinoma arising from short-segment barrett's esophagus in a young man. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 23605648 | Among the gi tract cancer, colorectal (crc) as well as esophageal cancer have raised the most attention over the past decades, as they both share a long precancerous stage (the adenoma in crc and barrett's esophagus in the case of esophageal adenocarcinoma) which provides a window of opportunity to intervene and prevent development of cancer.in this review, we will focus on both crc as well as esophageal adenocarcinoma (eac). |
| PubMedID- 24737143 | Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23606979 | barrett's esophagus is the source of barrett's adenocarcinoma and is characterized by the replacement of squamous epithelium with columnar epithelium in the lower esophagus due to chronic gastroesophageal reflux disease (gerd). |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 23591735 | We suggest that it may be useful to stratify the risk of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 20610142 | In contrast to adenocarcinoma arising from barrett's esophagus in western countries, the major disease phenotype in the asia-pacific region is esophageal squamous cell carcinoma which is attributed to the prevalence of smoking, alcohol, and betel quid chewing. |
| PubMedID- 19850156 | Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis. |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 26240798 | The incidence of esophageal adenocarcinoma arising from barrett's esophagus is about 0.5%. |
| PubMedID- 21995385 | Incidence of adenocarcinoma among patients with barrett's esophagus. |
| PubMedID- 22443641 | Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%. |
| PubMedID- 20698040 | The annual incidence of adenocarcinoma arising from barrett's esophagus (be) is approximately 0.5%. |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 20397052 | We therefore examined the association between these medications and the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 23525404 | For example, gej adenocarcinoma is associated with barrett's esophagus, while gastric cancer is associated with helicobacter pylori infection. |
| PubMedID- 24605249 | Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with barrett's esophagus by 41%, while statins could reduce the risk by 43%. |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 23111465 | While some studies suggest ppis result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with barrett's esophagus, others suggest that ppis have no effect. |
| PubMedID- 24795040 | Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus. |
| PubMedID- 26426603 | Cost-effectiveness decision tree model of endoscopic surveillance for esophageal adenocarcinoma among patients with definite barrett's esophagus. |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 19748616 | Background: barrett's esophagus is a precursor of esophageal adenocarcinoma, both of which are associated with gerd. |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
Page: 1